Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts & Scans -- Ignore unavailable to you. Want to Upgrade?

To: Jeff Jordan who wrote (2052)	8/22/2002 8:29:36 AM
From: Jeff Jordan	Respond to of 5125

FCSE 100% gain on xbox news...MS announcement hasn't helped FONX yet...it had a 400% move...remember. it should be doing better by now? finance.lycos.com CNBC way off with reporting MYGN bid...not down much now.

To: Jeff Jordan who wrote (2052)	8/22/2002 8:38:55 AM
From: RMP	Respond to of 5125

MYGN earnings may be ofset somewhat by the following: Thursday August 22, 8:07 am Eastern Time Dow Jones Business News Myriad Genetics/INDA -2: To Study R-flurbiprofen Drug SALT LAKE CITY -(Dow Jones)- Myriad Genetics Inc. (NasdaqNM:MYGN - News) filed an Investigational New Drug Application with the Food and Drug Administration to evaluate R-flurbiprofen as a drug to treat and prevent Alzheimer's disease. In a press release Thursday, the biopharmaceutical company said its planned Phase I trial will establish the safety profile and dosing regimens of R- flurbiprofen in healthy elderly volunteers. The study will enroll 48 subjects, and is expected to be completed within 12 months. After completing the Phase I study, Myriad plans to launch a Phase II human clinical trial to evaluate if R-flurbiprofen prevents cognitive decline in patients suffering from either early Alzheimer's disease or mild cognitive impairment, a less severe disease that primarily affects memory. Myriad said other ongoing studies are studying long-term use of R-flurbiprofen on cognitive impairment in a mouse model of Alzheimer's disease. - Thomas Gryta; Dow Jones Newswires; 201-938-5400